University of Bologna, Unit of Metabolic Diseases & Clinical Dietetics, 9, Via Massarenti, I-40138 Bologna, Italy.
Expert Opin Emerg Drugs. 2011 Mar;16(1):121-36. doi: 10.1517/14728214.2011.531700.
Non-alcoholic fatty liver disease (NAFLD) is becoming one of the most common causes of chronic liver disease worldwide. The economic and social cost of disease is very high and there is a need for effective treatments.
The available and potential future treatments for NAFLD are reviewed.
Weight loss remains the cornerstone of treatment of hepatic steatosis, but difficult to pursue. A pragmatic approach relies on generic recommendations for weight loss and physical activity in the whole population and limiting interventions to subject at risk of disease progression, but the type of preferred treatment remains a matter of debate. The large number and mechanistic diversity of drugs that have so far been investigated bear testimony to the lack of a specific, effective agent. Insulin resistance remains the pivotal alteration responsible for liver disease and its progression and insulin sensitizers are regarded as the treatment of choice. Several ongoing studies are testing the effectiveness of new approaches on histological outcomes and new metabolic pathways are under scrutiny.
非酒精性脂肪性肝病（NAFLD）正在成为全球最常见的慢性肝病病因之一。疾病的经济和社会成本非常高，因此需要有效的治疗方法。
对 NAFLD 的现有和潜在未来治疗方法进行了综述。
体重减轻仍然是治疗肝脂肪变性的基石，但很难实现。一种务实的方法依赖于对整个人群的体重减轻和体育活动的一般建议，并将干预措施限制在有疾病进展风险的患者，但首选的治疗类型仍然存在争议。迄今为止，已经研究了大量具有不同作用机制的药物，这表明缺乏特异性有效的药物。胰岛素抵抗仍然是导致肝脏疾病及其进展的关键改变，胰岛素增敏剂被认为是治疗的首选。目前正在进行多项研究，以测试新方法对组织学结果的有效性，新的代谢途径也在受到关注。
